Clinical Trials in Yiyang, China
2 recruiting
Showing 1–5 of 5 trials
Recruiting
Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
Chronic Obstructive Pulmonary Disease
Sanofi942 enrolled194 locationsNCT07190222
Recruiting
Phase 4
Efficacy and Safety Trials of Yangxinshi Tablets in the Treatment of Patients With Coronary Heart Disease Complicated by Cardiac Dysfunction
Cardiac dysfunctionCoronary Heart Disease
SPH Qingdao Growful Pharmacetical Co.,Ltd2,708 enrolled96 locationsNCT07110415
Recruiting
Phase 2
A Phase Ⅱ Study of RC108 in Combination With Furmonertinib for the First-line Treatment of EGFR-Mutated Combined MET-Positive Unresectable Locally Advanced or Recurrent Metastatic NSCLC
Non-small Cell Lung Cancer
RemeGen Co., Ltd.80 enrolled34 locationsNCT06962865
Recruiting
Phase 2
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus (SLE)
Beijing InnoCare Pharma Tech Co., Ltd.186 enrolled41 locationsNCT05688696
Recruiting
Chinese CKD-MBD Prevalence Survey (CRISS-MBD)
Chronic Kidney DiseasesChronic Kidney Disease-Mineral and Bone Disorder
Limeng Chen10,254 enrolled40 locationsNCT04714918